| Literature DB >> 31731683 |
Magdalena Valdivieso-Ugarte1, Carolina Gomez-Llorente1,2,3,4, Julio Plaza-Díaz1,2,3, Ángel Gil1,2,3,4.
Abstract
Essential oils (EOs) are a mixture of natural, volatile, and aromatic compounds obtained from plants. In recent years, several studies have shown that some of their benefits can be attributed to their antimicrobial, antioxidant, anti-inflammatory, and also immunomodulatory properties. Therefore, EOs have been proposed as a natural alternative to antibiotics or for use in combination with antibiotics against multidrug-resistant bacteria in animal feed and food preservation. Most of the results come from in vitro and in vivo studies; however, very little is known about their use in clinical studies. A systematic and comprehensive literature search was conducted in PubMed, Embase®, and Scopus from December 2014 to April 2019 using different combinations of the following keywords: essential oils, volatile oils, antimicrobial, antioxidant, immunomodulation, and microbiota. Some EOs have demonstrated their efficacy against several foodborne pathogens in vitro and model food systems; namely, the inhibition of S. aureus, V. cholerae, and C. albicans has been observed. EOs have shown remarkable antioxidant activities when used at a dose range of 0.01 to 10 mg/mL in cell models, which can be attributed to their richness in phenolic compounds. Moreover, selected EOs exhibit immunomodulatory activities that have been mainly attributed to their ability to modify the secretion of cytokines.Entities:
Keywords: antimicrobial; antioxidant; biofilm; essential oils; food preservation; immunomodulatory; volatile oils
Mesh:
Substances:
Year: 2019 PMID: 31731683 PMCID: PMC6893664 DOI: 10.3390/nu11112786
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
PICO (Population, Intervention, Comparison, Outcome) criteria for inclusion of studies.
| Parameter | Inclusion Criteria |
|---|---|
| Population | Studies performed in cells and animals, including humans |
| Intervention | Treatment with essential oil |
| Comparison | Essential oil vs. control |
| Outcome | Antimicrobial, antioxidant, and immunomodulatory effects |
Figure 1PRISMA flow chart for studies related with antibacterial, antioxidant, and immunomodulatory properties of essential oils.
Main characteristics of studies related with antibacterial properties of essential oils.
| Article | Plant Derived EOs | Main Components of EOs | Bacteria | MIC/MBC/IC50 |
|---|---|---|---|---|
| Aghraz et al. | MIC 200–800 μg/mL for | |||
| Alarcon et al. |
| β-myrcene (34.2%), α-pinene (24.3%), 7-epi-α-selinene (9.1%), and β-pinene (8.5%) | MIC 10 μg/mL | |
| Ashraf et al. |
| Hymoquinone, dithymoquinone, thymohydroquinone, and thymol | MIC ≥1000.0 ± 322.7 μg/mL | |
| Behbahani et al. |
| Thymol (28.45%) γ-terpinene (22.2%), ρ-cymene (17.90%), myristicin (13.55%), carvacrol (8.50%), and limonene (2.60%) | MIC, 1–8 mg/mL; MBC 1–16 mg/mL | |
| Boonyanugomol et al. |
| sabinene, γ-terpinene, α-terpinene, terpinene-4-ol, and (E)-1–(3,4-dimethoxyphenyl)butadiene |
| MIC/MBC: 7.00–9.24 mg/mL |
| Chaib et al. | MIC: 19–1250 μg/mL | |||
| Chen et al. | - | MIC 0.78%–3.13% | ||
| Chiboub et al. | MIC: 6.25–50 mg/mL | |||
| Condo et al. | ||||
| De Jesus et al. |
| Geranial (40%), neral (28%), citronella (9%) | MIC: 0.78–25 μL/mL | |
| Elshafie et al. | MIC: 1000–10,000 mg/L | |||
| Fadil et al. | Mixture of | Thyme MIC: 0.25% ( | ||
| Falsafi et al. |
| Carvacrol (45.5%), thymol (27.9%), p-cymene (4.4%), γ-terpinene (4.0%), α-pinene (1.5%), 1,8-cineole (1.3%), α-terpinene (1.2%), and E-caryophyllene (1.1%) |
| MIC: 0.035 μL/mL |
| Fournomiti et al. | MIC oregano: 0.9 mg/mL; 73.5 µg/mL; MIC thyme: 8.1 µg/mL; 9.5 µg/mL; 28.6 µg/mL against | |||
| Gadisa et al. | MIC: 0.39–6.25 μL/mL/MBC (0.78–12.5 μL/mL) against | |||
| Igwaran et al. |
| β-Ocimene (14.40%), m-tert-butyl-Phenol (9.41%), 2,6-dimethyl-, (E)-5,7-Octadien-4-one (7.14%), 1,2, | MIC ( | |
| Jaradat et al. |
| trans-geraniol (35.38%), α-citral (20.37%), β-citral (14.76%), cis-geraniol (7.38%), and 3-octanol (4.38%) | MIC: 0.25–0.5 mg/mL | |
| Lee et al. [ | Hibicuslide C | - | MIC range: 5.0–10.0 µg/mL | |
| Linde et al. |
| Apiol (50.3%), myristicin (14.0%), and β-phellandrene (14.6%) | MICs 0.04–1.0 mg/mL. MBCs 0.15–10.0 mg/mL | |
| Mahmoudzadeh et al. |
| thymol (36.4%), p-Cymene (31.4%), |
| MIC 0.05%–1.75%; |
| Man et al. | MICs/MBCs 0.1% to >50% | |||
| Marrelli et al. | ||||
| Meng et al. |
| Caryophyllene (13.11%) and α-caryophyllene (11.72%) |
| MIC/MBC: 3.125 mg/mL |
| Montironi et al. |
| Pulegone (51.7%) and menthone (37.8%) |
| MIC: 14.3–114.5 mg/mL/MBC: 114.5–229 mg/mL |
| Mutlu-Ingok et al. | Cardamom, cumin, and dill weed | Cumin: p-mentha-1,3-dien-7-al (26.7%), cumin aldehyde (24.1%), γ-terpinene (16.9%), and | MIC/MBC: 0.05 L/mL, cumin, Cardamon/cumin MIC/MBC: 0.025 L/mL | |
| Okoh et al. |
| Linalool, d-limonene, β-caryophyllene, and linalyl acetate were the major compounds | MIC: 0.15–0.20 mg/mL | |
| Okoh et al. |
| Phytol, germacrene D, 𝛼-copaene, 𝛼-terpinene, and limonene were the major compounds | MIC/MBC: 0.025–0.10 mg/; | |
| Oukerrou et al. |
| 𝛽-spathulenol (15.61%), ar-curcumene (14.15%), trans-caryophyllene oxide (14.14%), and neral (10.02%) | MIC: 2.84–8.37 mg/mL | |
| Paredes et al. |
| Methyl cinnamate (44.9%), p-cymenol (27.2%), |
| MIC: 0.4 mg/mL |
| Patra et al. |
| Hexadecanoic acid, nonadecadiene, tetradecanoic acid, tridecanol, and azetidine | MIC/MBC: 12.5–25 mg/mL | |
| Pereira et al. [ |
| - |
| MIC: 6% |
| Porfirio et al. [ |
| Geranial, neral, p-cymene, geranic acid, carvone, and limonene were the major compounds |
| MIC 0.5–1 mg/mL; MBC: 0.5–2 mg/mL |
| Puškárová et al. [ | - | MIC/MBC: 0.025%–0.5% | ||
| Sakkas et al. [ | MIC/MBC values ranged from 0.12% to 1.50% ( | |||
| Salem et al. [ | Terpinen-4-ol (23.7%), α-phellandrene (19.2%), α-citronellol (17.3%), and citronellal were the major constituents of | MIC | ||
| Semeniuc et al. [ | Parsley, lovage, basil, and thyme | β-myrcene, | ||
| Sharafiti Chaleshtori et al. [ | MIC: 0.351–2.812 mg/mL | |||
| Sharifi et al. [ |
| MICs of | ||
| Sharifi-Rad et al. [ | cis-β-guaiene (34.2%), limonene (20.3%), borneol (11.6%), and bornyl acetate (4.5%) | MIC | ||
| Smeriglio et al. [ | 4-Carene, α-pinene, and | MIC/MBC: 7.11 mg/mL inhibited the growth of all the tested strains, with the exception of | ||
| Snoussi et al. [ | ||||
| Soliman et al. [ |
| Benzaldehyde derivative was the major compound | MIC: 180.0–200.0 µg/mL | |
| Tibyangye et al. [ |
| Linalool and geraniol were the major compounds | MIC: 0.78–22 μg/mL | |
| Touihri et al. [ |
| Methyl methanethiosulfinate, 3-vinyl-1,2-dithiacyclohex-5-ene, and diallyl trisulfide were the major compounds | MIC: 0.078–2.5 mg/mL | |
| Ušjak et al. [ | β-pinene, (Z)-β-ocimene, and α-pinene were the major compounds | |||
| Utegenova et al. [ |
| α-pinene (47.8%), β-pinene (7.1%), sabinene (20.5%), β-phellandrene (6.5%), and trans-verbenol (7.4%) | MRSA | IC50: 19.1–22.9 μg/mL |
| Vieira et al. [ | MIC: 6–25 mg/mL | |||
| Xu et al. [ |
| Eugenol (76.23%), β-caryophyllene (11.54%), caryophyllene oxide (4.29%), and eugenyl acetate (1.76%) |
| MIC: 0.625 mg/mL |
| Zhao et al. [ | MIC: 100.0–800.0 g/mL |
Abbreviations: EO, essential oil; MIC, minimal inhibitory concentration; MBC, minimal bactericidal concentration; IC50 half-maximal inhibitory concentration; MRSA, methicillin-resistant S. aureus.
Main characteristics of studies related with antioxidant properties of essential oils.
| Article | Plant Derived EOs | Main Components of EOs | Method | Antioxidant Effects |
|---|---|---|---|---|
| Bag et al. [ | Bay leaf, black pepper, coriander, cumin, garlic, ginger, mustard, onion, and turmeric | Coriander and cumin seed oil, linalool, p-coumaric acid | DPPH method | Coriander 150.62 (µg/mL), cumin 163.50 (µg/mL), mustard 155.16 (µg/mL) |
| Djenane et al. [ | Orange ( | Limonene (77.37%) for orange EO; linalyl acetate (37.28%), linalool (23.36%) for bergamot EO; and limonene | Antioxidant effect in treated sardine | A reduction of 2.50 log10 CFU/g was recorded during the third day of storage |
| Ehsani et al. [ | DPPH, BCBT, and ABTS assay | Both EOs showed strong activity in the maintenance of β-carotene molecules, which was higher than that of ascorbic acid | ||
| Hu et al. [ | α–pinene, cyperene, α–cyperone, and cyperotundone were the major compounds | DPPH and ABTS radicals | DPPH radicals were far lower than that of Trolox (13.1 μg/mL); however, ABTS radicals were significantly higher than Trolox (84.7 μg/mL) | |
| Jaradat et al. [ |
| Linalyl acetate, 𝛽-linalool, 2-undecanone, and 2-nonanone were the major compounds | DPPH method | Percentages of inhibition for |
| Kazemi et al. [ | DPPH, FRAP, and BCBT assays | |||
| Marin et al. [ | DPPH and FRAP assays | |||
| Marrelli et al. [ | Six different populations of | Limonene, carvacrol-methyl-ether, and carvacrol were the major compounds | DPPH and BCBT assays | Samples showed a modest DPPH value of 320.9 μg/mL, and BCBT of 4.68 μg/mL. |
| Okoh et al. [ | 2-Methylphenyl formate, α–terpinene, and caryophyllene were the major compounds | DPPH, ABTS, nitric oxide, and lipid peroxyl | The EOs demonstrated strong ability in ABTS, lipid peroxide, and nitric oxide radical assays in a concentration-dependent manner | |
| Okoh et al. [ | Phytol, germacrene D, 𝛼-copaene, 𝛼-terpinene, and limonene were the major compounds | DPPH, ABTS, nitric oxide, and lipid peroxyl | The stem showed that the antiradical strength was superior to leaf EO | |
| Okoh et al. [ | Linalool, d-limonene, β-caryophyllene, and linalyl acetate were the major compounds | DPPH, ABTS, nitric oxide, and lipid peroxyl | The EOs demonstrated strong ability in DPPH, ABTS, nitric oxide and lipid peroxyl assays in a concentration-dependent manner | |
| Ouedrhiri et al. [ | DPPH method | |||
| Pirbalouti et al. [ |
| α-pinene, and cis-β-ocimene were the major compounds | DPPH method | The highest antioxidant activity was obtained from the oil of the Kallar population (488 µg/mL) and butylhydroxyanisole as a positive control (321 µg/mL) |
| Poaty et al. [ | Balsam fir, black spruce, white spruce, tamarack, jack pine, eastern white cedar, and Labrador tea EOs | α–pinene, β-pinene, δ-3-carene, and limonene were the major compounds. α–thujone was the main compound in white cedar | DPPH, FRAP assays | DPPH (concentration providing 50% inhibition ≥7 mg/mL) |
| Semeniuc et al. [ | Parsley, lovage, basil, and thyme EOs | β-myrcene, | TEAC assay | The highest antioxidant capacity was found in thyme oil |
| Shakeri et al. [ | β-caryophyllene, limonene, and myrcene were the major compounds | The DPPH, and β-Carotene/linoleic acid assay | The oil was considerably active in the DPPH assay (100.40 ± 0.03 µg/mL) | |
| Sharafati Chaleshtori et al. [ | FRAP | |||
| Smeriglio et al. [ | 4-carene, α-pinene, and | Determination of total phenolic compounds, DPPH, TEAC, FRAP, chelating capacity on Fe2+, BCBT assays, superoxide anion (O2−) scavenging assay and hydroxyl radical (−OH) scavenging assay | The | |
| Snoussi et al. [ |
| Limonene, 1,8-cineole, and carvone were the major compounds | DPPH method, reducing power, chelating power, and BCBT assays | DPPH IC50 3.08 ± 0.07, reducing power EC50, 2.49 ± 0.07, chelating power IC50, 6.33 ± 0.12, and BCBT 6.4 ± 0.07 |
| Salem et al. | Terpinen-4-ol (23.7%), α-phellandrene (19.2%), α-citronellol (17.3%), and citronellal were the major constituents of | Standard butylhydroxytoluene | ||
| Zhao et al. | DPPH and BCBT assays | Three EOs have a similar antioxidant capacity in both evaluated methods |
Abbreviations: EOs: essential oils; ABTS, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid); BCBT, β-carotene bleaching test; CFU, colony-forming unit; DPPH, (2,2-diphenyl-1-picrylhydrazyl); FRAP, ferric-reducing antioxidant power; TEAC, Trolox equivalent antioxidant capacity.
Main characteristics of studies related with immunomodulatory properties of essential oils in cells.
| Author | Cell Line | Plant Derived EOs | EOs Concentration | Main Components of EOs | Exposure Time | LPS Stimulation | Main Results |
|---|---|---|---|---|---|---|---|
| Chen et al. | THP-1 human monocyte/macrophage cell line | Kanuka and manuka | 0.1–0.5–1–5–10% | 48 h | yes (20 µg/mL) | EOs have no major toxic side effects on THP-1 cells. Kanuka and manuka EOs reduced the LPS-induced TNF-α secretion but have no effect on IL-4 secretion. Kanuka and manuka EO have no effect on unstimulated THP-1 cells. | |
| Chen et al. [ | C57BL/6 mouse bone marrow-derived dendritic cells (DCs) | 1–2–4 × 105- and 5 × 104-fold dilution | Terpene aldehydes (75.09%) were the most abundant compounds | Cytotoxicity assay: 24 h; TNF-α assay: 6 h; IL-12 assay: 12 h | yes (100 ng/mL) | A slight cytotoxic effect was observed at 5 × 104 -fold diluted EO. Release of TNF-α and IL-12 by LPS-induced DCs were inhibited by EO in a dose-dependent fashion (IC50 of 1 × 105- and 2 × 105-fold dilution for TNF-α and IL-12, respectively). | |
| Chen et al. [ | Murine macrophage RAW264.7 cells |
| 270, 90, 30, and 10 µg/mL) | Cineole, camphor, (−)-borneol, and α-(−)-thujone were the major compounds | 16 h | yes (1 µg/mL) | In LPS-induced cells, the EOs inhibited the release of NO, PGE2, and ROS and TNF-α, IL-6, IFN-β and MCP-1. In addition, EOs downregulate the gene and protein expression of iNOS and COX-2 without affecting its enzymatic activity. EOs also inhibited the phosphorylation of JAK2 and STAT1/3 but did not affect the MAPK and NF-κB cascades. |
| Cheng et al. [ | Murine macrophage RAW264.7 cell | Oregano ( | ≤10 μg/mL | Carvacrol and thymol were the major compounds | 12 h | yes (1 µg/mL) | Low dose of EOs (1.25–20 μg/mL) did not produce any toxicity. In LPS-induced RAW264.7 cells, pretreatment with the EOs reduced the expression and secretion of IL-1β, IL-6, and TNF-α. Inhibition of LPS-induced MAPK, PKB, and NF-κB was also observed. The EOs also inhibited the LPS-induced elevation of NADPH oxidase and oxidative stress |
| Krifa et al. [ | Splenocyte suspension from Balb/c mice; Murine melanoma B16F10 cell line |
| Splenocyte suspension: 1.25, 2.5, 5, and 10 μg/mL. B16F10 cell line: 25, 50, 100, 200, and 400 μg/mL. | Sabinene, α-pinene, limonene, and terpinen-4-ol were the major compounds | 48 h | yes (5 μg/mL) | EOs treatment was able to promote LPS-stimulated splenocyte proliferation. In B16F10 cells, incubation with the EOs inhibited cell proliferation in a dose- and time-dependent fashion (IC50: 80 μg/mL). In addition, EOs treatment was also able to increase the number of apoptotic cells. |
| Ma et al. [ | L02 cell line; Human lung adenocarcinoma A549 cell line; Murine macrophage RAW264.7 cell | 25, 50, 100, and 200 μg/mL | Flavonoids, saponins, polysaccharides EO, coumarin, and alkaloids | 24 h | yes (1 µg/mL) | EOs have no major toxic side effects on L02 cells, and even promoted cell proliferation. In the A549 cell line, EOs promote the proliferation of cancer cells. NO production was inhibited in LPS-induced RAW264.7 cells treated with EOs at 50 and 100 μg/mL. In addition, EOs treatment reduces the secretion of IL-6, but has no effect on TNF-α gene expression. Furthermore, EOs decreased lipid accumulation in ox-LDL-induced RAW264.7 cell, and decreased the secretion of IL-6. | |
| Marelli et al. [ | Murine macrophage RAW264.7 cells | 25–1000 μg/mL | Limonene, carvacrol-methyl-ether, and carvacrol were the major compounds | 24 h | yes (1 µg/mL) | In LPS-stimulated RAW264.7 cells, all EOs from | |
| Özek et al. [ | Human blood isolated neutrophils from healthy donors; bone marrow leukocytes isolated from Balb/c mice |
| 1% | (E)-Propenyl sec butyl disulfide, (Z)-Propenyl sec butyl disulfide, and 10-Epi-g-eudesmol were the major compounds | Ca2+ flux assay: 0.06 h; ROS production: 0.5 h | no | EOs activated human neutrophil Ca2+ flux; this activation was dose-dependently inhibited by capsazepine, a TRPV1 channel antagonist. This effect was confirmed on TRPV1 channel-transfected HEK293 cells. Furthermore, EOs also activated SOD-inhibitable ROS production in both human neutrophils and mouse bone marrow phagocytes. |
| Park et al. [ | Murine macrophage RAW264.7 cells |
| 1, 10, 50, and 100 μg/mL | α-terpinyl acetate, β-phellandrene, β-myrcene, limonene, bornyl acetate, γ-terpinene, β-thujaplicin, and α-terpineol | 1 h | yes (1 µg/mL) | In LPS-stimulated cells, EOs treatment reduced nitric oxide, TNF-α, and IL-6 production, and inhibited iNOS and COX-2 expression. |
| Puskárova et al. [ | human embryo lung HEL12469 cells | 0.0025–1.0 μL/mL | - | 24 h | no | EOs present toxic side effects at higher concentrations. Treatment with EOs did not induce any significant increase in DNA strand breaks; only | |
| Smeriglio et al. [ | Human blood isolated lymphocytes from healthy donors | 20, 17.5, 15, 12.5, 10, 7.5, 5, and 1 μg/mL | 4-Carene, α-pinene, and | 24 h | no | EOs did not show any cytotoxic effects. In tert-butyl hydroperoxide-treated lymphocytes, incubation with EOs (20–12.5 μg/mL) significantly increased cell viability. | |
| Touihri et al. [ | Human colonic adenocarcinoma HT29-D4 and Caco-2 cell lines | 10, 20, 30, and 40 μg/mL | Methyl methanethiosulfinate, 3-vinyl-1,2-dithiacyclohex-5-ene, and diallyl trisulfide were the major compounds | Cytotoxicity assay: 5 h; Proliferation assay: 72 h | no | EOs did not show cytotoxic effects. Antiproliferative assay depicted that the number of cells was reduced by the incubation of HT29-D4 and Caco-2 cells with EOs in a dose-dependent fashion. | |
| Ušjak et al. [ | Human cervix Hela cell; human colon carcinoma LS174 cell; non-small cell lung carcinoma A549; human normal fetal lung fibroblast MRC-5 cell | 12.5, 25, 50, 100, and 200 μg/mL | β-pinene, (Z)-β-ocimene, and α-pinene were the major compounds | 72 h | no | The cytotoxic effect of EOs was prominent against HeLa, LS174, and A549 cell lines. EOs did not show toxicity side effects against normal MRC-5 cell (IC50 >200 μg/mL). | |
| Wang et al. [ | Murine macrophage RAW264.7 cells |
| 1.25, 2.5, 5.0, 10, and 20 mg/mL | β–phellandrene, myristicin, and elemicine were the major compounds | 1 h | yes (100 ng/mL) | In LPS-stimulated RAW264.7 cells, only a high concentration of EOs (40 mg/mL) showed a negative effect on cell viability. In addition, incubation with EOs inhibited the production of TNF-α, IL-1β, and IL-6, whereas it increased the release of IL-10. EOs also inhibited the secretion of NO and PGE2. |
Abbreviations: EO: essential oil; LPS: lipopolysaccharide; IL: interleukin; TNF-α: tumor necrosis factor alpha; NO: nitric oxide; iNOS: inducible nitric oxide synthase; MAPK: mitogen-activated protein kinase; PKB: protein kinase B; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; COX-2: cyclooxygenase 2; PGE2: prostaglandin E2; ox-LDL: oxidized low-density lipoprotein.
Main characteristics of studies related with immunomodulatory properties of essential oils in animals.
| Author | Animal | Plant Derived EOs | EOs Concentration | Main Components of EOs | EOs Administration | Treatment Duration | Main Results | |
|---|---|---|---|---|---|---|---|---|
| Adaszynska-Skwirzynska et al. [ | Broiler chickens |
| 0.4 mL/L | Linalool and linalool acetate were the major compounds (>80%) | Drinking water (6 h/day) | From 1 to 42 d of age and from 22 to 42 d of age | Broiler chickens treated with EO weighed an average of 6.35% more than those in the control group. No differences were found in feed and water intake, survival rate, or biochemical parameters. EOs intake also has an impact on ileum gastrointestinal microbiota (pathogenic microorganisms decreased, while the number of probiotic bacteria increased). | |
| Altop et al. [ | Broiler chickens | Liquidambar | 0.0405, 0.0811, and 0.1622 g/kg | γ-Terpinen, terpinen-4-ol, and α-terpinene were the major compounds | Basal diet supplemented (ad libitum) | 42 d | Treatment with EOs, mainly at 0.0811 g/kg concentration, improved growth performance and carcass traits while reducing blood cholesterol levels and | |
| Cetin et al. [ | Broiler chickens | Individual EO: 100 mg/kg. EO mixture: 100, 200 and 400 mg/kg | Rosemary oil, 1,8-cineol, α-pinene, and camphene; oregano oil, carvacrol; and fennel oil, trans-anethole, and fenchone | Basal diet supplemented (ad libitum) | 42 d | Dietary supplementation increased the body weight of broilers at 7, 14, and 21 d of age. The blend of EO at 400 mg/kg significantly increased | ||
| Chen et al [ | C57BL/6 mouse | 50- and 100-fold diluted | Terpene aldehydes (75.09%) were the most abundant compounds | Abdomens were painted | 5 d | Treatment with EO showed an inhibitory effect on contact hypersensitivity response. | ||
| Chen et al. [ | C57BL/6 mouse |
| 750, 250, and 83 mg/kg | Cineole, camphor, (−)-borneol, and α-(−)-thujone were the major compounds | Oral administration | 30 minutes before 12-O-tetradeconoylphorbol-13-acetate application | Oral administration of the EO significantly attenuated TPA-induced mouse ear edema and decreased the protein level of COX-2 | |
| Gomes Cairo et al. [ | Weaned pigs |
| 0.5, 1.0, and 1.5 g/kg | 𝛿-3-carene, 𝛼-phellandrene, limonene, and 𝛼-pinene were the major compounds | microencapsulated product | 14 d | EO treatment modulated the gastrointestinal microbiota by increasing | |
| Li et al. [ | Weaned piglets | Carvacrol and thymol | Carvacol: 62.5 mg/kg; Thymol: 7.5 mg/kg | N-(2-hydroethyl)-iminodiacetic acid 2 | Basal diet supplemented (ad libitum) | 30 d | EO treatment significantly increased the relative abundance of | |
| Park et al. [ | Carrageenan-induced paw edema model (C57BL/6) and thioglycollate-induced peritonitis model (C57BL/6) |
| 5 and 10 mg/kg | α-terpinyl acetate, β-phellandrene, β-myrcene, limonene, bornyl acetate, γ-terpinene, β-thujaplicin, and α-terpineol | Intraperitoneal administration | 1 h prior to inflammation-induced treatment | EO treatment reduced the levels of IL-6 and IL-1β in paw homogenates and in peritoneal fluid. In thioglycollate-induced peritonitis levels of TNF-α in peritoneal fluid. | |
| Sutili et al. [ | Silver catfish | Daily bath for | 1 h during 5 d | Fish exposed to EOs showed significant lower hematocrit values and higher complement system activity and plasma cortisol levels. There was no significant difference in the survival of fish challenged with | ||||
| Yang et al. [ | Weaned piglets | Mixture of EOs and organic acids: cinnamaldehyde (15%), thymol (5%), citric acid (10%), sorbic acid (10%), malic acid (6.5%) and fumaric acid (13.5%) | 1 kg/ton | Basal diet supplemented (ad libitum) | 28 d | Diet supplementation with the mixture improved the final body weight and average daily gain, increased the concentration of serum complement 4, and enhanced the isovaleric acid fecal concentration. Regarding the gastrointestinal microbiota composition in fecal samples, the mixture treatment increased the beta diversity. | ||
Abbreviations: EO, essential oil; d: days; TNF-α: tumor necrosis factor alpha; TPA: 12-O-tetradeconoylphorbol-13-acetate; COX-2: ciclooxigenase 2.